Roche and Blue­print agree to end col­lab­o­ra­tion for can­cer drug Gavre­to

Roche is re­turn­ing de­vel­op­ment and com­mer­cial­iza­tion rights for can­cer drug Gavre­to to Blue­print Med­i­cines.

The two com­pa­nies are dis­solv­ing their col­lab­o­ra­tion fol­low­ing a Roche de­ci­sion to opt out for “strate­gic rea­sons,” a Blue­print spokesper­son told End­points News in an email. The re­turn of the rights to Blue­print ex­cludes Gavre­to in Greater Chi­na where Roche al­ready has a li­cense agree­ment with CStone Phar­ma­ceu­ti­cals to com­mer­cial­ize the drug, ac­cord­ing to a news re­lease on Thurs­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER